Nanomedical Devices and Cancer Theranostics
Mohamed Moumaris1, 2, *, Jean-Michel Bretagne1, Nisen Abuaf2, 3
1 Groupe Hospitalier Universitaire Paris Centre, Département des Investissements, AP-HP, 1 Place du Parvis Notre Dame, 75004 Paris, France
2 Laboratoire d'Hématologie et d’Immunologie, Hôpital Rothschild, 5 Rue Santerre, 75012 Paris and Hôpital Tenon, 4 Rue de la Chine 75020 Paris, Groupe Hospitalier Universitaire Paris Est, AP-HP et Département d'Immunologie, Faculté de Médecine, Université Pierre et Marie Curie, Sorbonne Université, Paris, France
3 Hôpital Tenon, Groupe Hospitalier Universitaire Paris Est, AP-HP et Université Pierre et Marie Curie, 4 Rue de la Chine, 75020 Paris, France
Abstract
The current therapies against cancer showed limited success. Nanotechnology is a promising strategy for cancer tracking, diagnosis, and therapy. The hybrid nanotechnology assembled several materials in a multimodal system to develop multifunctional approaches to cancer treatment. The quantum dot and polymer are some of these hybrid nanoparticle platforms. The quantum dot hybrid system possesses photonic and magnetic properties, allowing photothermal therapy and live multimodal imaging of cancer. These quantum dots were used to convey medicines to cancer cells. Hybrid polymer nanoparticles were utilized for the systemic delivery of small interfering RNA to malignant tumors and metastasis. They allowed non-invasive imaging to track in real-time the biodistribution of small interfering RNA in the whole body. They offer an opportunity to treat cancers by specifically silencing target genes. This review highlights the major nanotechnology approaches to effectively treat cancer and metastasis.
Keywords: Nanotechnology, Nanoparticle, Cancer, Diagnosis, Therapy, Theranostic.
Article Information
Article History:
Received Date: 30/10/2019
Revision Received Date: 11/03/2020
Acceptance Date: 12/03/2020
Electronic publication date: 21/04/2020
Collection year: 2020
© 2020 Moumaris et al.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at:
https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
* Address correspondence to this author at the Laboratoire d'Hématologie et d’Immunologie, Hôpital Rothschild, 5 Rue Santerre, 75012 Paris and Hôpital Tenon, 4 Rue de la Chine 75020 Paris, Groupe Hospitalier Universitaire Paris Est, AP-HP et Département d'Immunologie, Faculté de Médecine, Université Pierre et Marie Curie, Sorbonne Université, Paris and Hôtel-Dieu, Groupe Hospitalier Universitaire Paris Centre, Département des Investissements, AP-HP, 1 Place du Parvis Notre Dame, 75004 Paris, France; Tel: 0033762122825; E-mail: mohamed.moumaris@orange.fr
Open Peer Review Details |
Manuscript submitted on 30-10-2019 |
Original Manuscript |
Nanomedical Devices and Cancer Theranostics |